IO Biotech Inc. is on the Cruelty-Free Investing usage of animals list because they undertake pre-clinical studies on animals to examine the safety profile of their medications.
The company stated in the following report that they exploit animals for product testing.
“The anti-tumor activity of mIO102 was accompanied by a substantial reduction of IDO1 expression in TME. In contrast, animals treated with the IDO inhibitor, epacadostat, exhibited little changes in the IDO expression in TME with no durable responses, highlighting the differential MoA between IO102 and IDO small molecule inhibitors.” (Page 142) Read the full document
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company’s lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Company Website: https://www.iobiotech.com